4.795

3.40% -0.205

Silence Therapeutics Plc Adr (SLN)

Overview News Price History Discussions Forecast

Silence Therapeutics Plc Adr stock is traded at $4.795, with a volume of 14,052. It is down -3.40% in the last 24 hours and down -13.13% over the past month. Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Previous Close:

$5.00

Open:

$4.97

24h Volume:

14,052

Relative Volume:

0.02

Market Cap:

$236.07M

Revenue:

$31.37M

Net Income/Loss:

$-53.77M

P/E Ratio:

-3.2985

EPS:

-1.4537

Net Cash Flow:

$-49.02M

1W Performance:

-0.21%

1M Performance:

-13.13%

6M Performance:

-69.51%

1Y Performance:

-79.71%

1-Day Range:

$4.785

$5.10

1-Week Range:

$4.70

$5.16

52-Week Range:

$4.06

$27.72

Silence Therapeutics Plc Adr Stock (SLN) Company Profile

Name

Silence Therapeutics Plc Adr

Sector

Healthcare (1174)

Industry

Biotechnology (677)

Phone

Address

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

SLN's Discussions on Twitter

Compare SLN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLN Silence Therapeutics Plc Adr	4.80	236.07M	31.37M	-53.77M	-49.02M	-1.4537
VRTX Vertex Pharmaceuticals Inc	480.77	123.34B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.62	76.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	648.37	39.34B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	251.00	32.49B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	116.81	28.26B	3.30B	-501.07M	1.03B	-2.1146

Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Goldman	Sell
Dec-02-24	Reiterated	BMO Capital Markets	Outperform
Sep-03-24	Initiated	Jefferies	Buy
Jan-31-24	Initiated	BMO Capital Markets	Outperform

Silence Therapeutics Plc Adr Stock (SLN) Latest News

Feb 20, 2025

BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.

Feb 20, 2025

Feb 11, 2025

Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa

Feb 11, 2025

Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News

Feb 11, 2025

Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex

Feb 11, 2025

Feb 10, 2025

Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater

Feb 10, 2025

Feb 03, 2025

Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Feb 03, 2025

Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com

Feb 03, 2025

H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa

Feb 03, 2025

Jan 07, 2025

European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN

Jan 07, 2025

Dec 18, 2024

Top 3 Health Care Stocks That May Explode In Q4 - Benzinga

Dec 18, 2024

Dec 17, 2024

Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com

Dec 17, 2024

Dec 10, 2024

Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India

Dec 10, 2024

Dec 09, 2024

Silence Therapeutics announces additional results from SANRECO study - TipRanks

Dec 09, 2024

Nov 24, 2024

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN

Nov 24, 2024

Nov 20, 2024

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance

Nov 20, 2024

United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India

Nov 20, 2024

Nov 19, 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com

Nov 19, 2024

Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks

Nov 19, 2024

SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks

Nov 19, 2024

Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga

Nov 19, 2024

Nov 17, 2024

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Nov 14, 2024

Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks

Nov 14, 2024

Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024

Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港

Oct 16, 2024

Oct 01, 2024

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance

Oct 01, 2024

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com

Sep 30, 2024

Sep 25, 2024

Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance

Sep 25, 2024

Sep 24, 2024

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance

Sep 24, 2024

Sep 02, 2024

It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News

Sep 02, 2024